Advanced Oncotherapy is a specialist developer and provider of the next generation of particle therapy systems that makes radiation less toxic for patients. Our aim is to create a bright future in cancer care with our advanced LIGHT technology. Vision: To develop a more affordable proton-based radiotherapy system, using an innovative and clinically more effective technology, and saving more cancer lives. Mission: To facilitate the wider use of radiation with protons for treating all forms of radio-sensitive cancers by commercialising a novel technology, and building on the success and scientific know-how of CERN (Centre Européen pour la Recherche Nucléaire).
Type
Public
HQ
London, GB
Founded
1994
Size (employees)
51 (est)
Advanced Oncotherapy was founded in 1994 and is headquartered in London, GB
Report incorrect company information

Advanced Oncotherapy Office Locations

Advanced Oncotherapy has offices in London, Syracuse and Rolle
London, GB (HQ)
4-7 Manchester St
Rolle, CH
23 Route de Genève
Syracuse, US
1009 E Fayette St
Show all (3)
Report incorrect company information

Advanced Oncotherapy Financials and Metrics

Advanced Oncotherapy Financials

Advanced Oncotherapy's revenue was reported to be £84.24 k in FY, 2015 which is a 20.8% decrease from the previous period.
GBP

Net income (FY, 2016)

(10.4 m)

EBITDA (FY, 2016)

(12.7 m)

EBIT (FY, 2016)

(13.1 m)

Market capitalization (31-Oct-2017)

21.7 m

Closing share price (31-Oct-2017)

0.3

Cash (31-Dec-2016)

1.4 m

EV

20.8 m
Advanced Oncotherapy's current market capitalization is £21.7 m.
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.7 m1.8 m2.1 m2.9 m3.4 m1.4 m71 k100 k68.9 k106.4 k84.2 k

Revenue growth, %

54%(21%)

Cost of goods sold

73 k84 k163 k416 k455.3 k1.2 m713 156 k202.7 k

Gross profit

1.7 m1.7 m2 m2.4 m3 m200 k99.3 k(87 k)(96.3 k)
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

7 m2.3 m119 k2.5 m268.6 k148.4 k24.2 k57.8 k148.8 k1.5 m9 m1.4 m

Accounts Receivable

339 k360 k152 k128.6 k173.4 k2.1 m1.1 m2.9 k28.6 k73.6 k

Inventories

1 k37.2 k1.1 m4.4 m7.4 m

Current Assets

7.3 m4.6 m665 k3 m781.1 k2.7 m1.5 m1.5 m1.4 m3.2 m16.7 m12.5 m
GBPFY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(383 k)678 k1.5 m(1.7 m)(1.8 m)(3.4 m)(2.3 m)(1.9 m)(3.4 m)(5.7 m)(5.8 m)(10.4 m)

Cash From Operating Activities

1.7 m1.4 m(625.5 k)(742.1 k)(4.3 m)(774.2 k)(1.4 m)(2.9 m)(6.6 m)(9.8 m)(10.9 m)

Cash From Financing Activities

3.4 m5.6 m13.9 m4.9 m(19.5 m)(23.4 m)2.4 m2.5 m9.2 m21.1 m13.1 m

Net Change in Cash

4.6 m4.2 m4.3 m(2.2 m)(507.3 k)(90.4 k)386.8 k91.2 k1.3 m7.5 m(7.5 m)
GBPY, 2016

EV/EBITDA

-1.6 x

EV/EBIT

-1.6 x

EV/CFO

-1.9 x

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Advanced Oncotherapy Online and Social Media Presence

Embed Graph
Report incorrect company information